Liquidia Co. (NASDAQ:LQDA) Shares Bought by Eversept Partners LP

Eversept Partners LP grew its stake in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 314.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 571,305 shares of the company's stock after acquiring an additional 433,356 shares during the quarter. Eversept Partners LP owned about 0.67% of Liquidia worth $6,719,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC acquired a new stake in shares of Liquidia during the fourth quarter worth $59,000. Summit Investment Advisors Inc. increased its holdings in shares of Liquidia by 35.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock valued at $78,000 after purchasing an additional 1,719 shares during the period. EntryPoint Capital LLC purchased a new position in shares of Liquidia in the fourth quarter worth about $154,000. KLP Kapitalforvaltning AS purchased a new stake in Liquidia in the fourth quarter valued at approximately $169,000. Finally, Arizona State Retirement System raised its position in Liquidia by 20.3% during the 4th quarter. Arizona State Retirement System now owns 15,888 shares of the company's stock worth $187,000 after buying an additional 2,685 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on LQDA. Needham & Company LLC reissued a "buy" rating and set a $25.00 target price on shares of Liquidia in a report on Thursday, April 10th. Scotiabank reaffirmed an "outperform" rating on shares of Liquidia in a research note on Thursday, March 20th. Finally, HC Wainwright restated a "buy" rating and issued a $29.00 target price on shares of Liquidia in a report on Thursday, March 20th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $26.63.

Insider Activity

In other Liquidia news, insider Jason Adair sold 1,856 shares of the business's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $25,185.92. Following the completion of the transaction, the insider now directly owns 184,304 shares in the company, valued at approximately $2,501,005.28. The trade was a 1.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Rajeev Saggar sold 2,450 shares of the company's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $13.67, for a total transaction of $33,491.50. Following the transaction, the insider now directly owns 263,152 shares of the company's stock, valued at approximately $3,597,287.84. This represents a 0.92 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,128 shares of company stock valued at $450,072. Insiders own 30.10% of the company's stock.

Liquidia Stock Up 0.6 %

Shares of LQDA traded up $0.09 during trading on Friday, reaching $14.12. 584,669 shares of the company traded hands, compared to its average volume of 959,816. Liquidia Co. has a twelve month low of $8.26 and a twelve month high of $16.81. The stock has a 50-day simple moving average of $14.44 and a 200-day simple moving average of $12.87. The stock has a market cap of $1.20 billion, a PE ratio of -8.66 and a beta of 0.23.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $2.92 million for the quarter, compared to analysts' expectations of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. On average, equities research analysts predict that Liquidia Co. will post -1.51 EPS for the current year.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).